Pharmafair
Executive Summary
FDA announces in the July 22 Federal Register that it is withdrawing Pharmafair's approvals for three ANDAs because of untrue statements, discrepancies and omissions in data supporting the approvals. The three withdrawals cover betamethasone valerate cream 0.1%, betamethasone valerate ointment 0.1%, and prednisolone acetate 0.2% with sulfacetamide sodium ophthalmic suspension.